REAL WORLD OUTCOMES OF VEDOLIZUMAB FOR INFLAMMATORY BOWEL DISEASE POST LIVER TRANSPLANTATION

被引：0
|
作者：
Peverelle, Matthew
Mills, Christopher D.
Testro, Adam
De Cruz, Peter
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1901
引用
收藏
页码：S845 / S845
页数：1
相关论文
共 50 条
  • [41] Treatment persistence and clinical outcomes of vedolizumab in inflammatory bowel disease patients in Taiwan: real-world evidence from the TSIBD registry
    Tai, Wei-Chen
    Tu, Chia-Hung
    Chou, Jen-Wei
    Feng, I-Che
    Chung, Chen-Shuan
    Shieh, Ming-Jium
    Yen, Hsu-Heng
    Hsu, Wen-Hung
    Lu, Chien-Yu
    Lu, Lung-Sheng
    Tang, Shu-Lun
    Lien, Pei-Wen
    Ye, Yizhou
    Dolin, Paul
    Wei, Shu-Chen
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 305 - 305
  • [42] REAL WORLD COMPARATIVE RISK OF SERIOUS INFECTION WITH ADALIMUMAB, VEDOLIZUMAB, AND INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Osterman, Mark T.
    Long, Millie D.
    Singh, Siddharth
    Meyer, Nicole
    Feng, Chaoling
    Higgins, Kate
    Hepp, Zsolt
    Arikan, Dilek
    Wang, Anthony
    Feagan, Brian G.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S365 - S365
  • [43] Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naive patients with inflammatory bowel disease
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Adsul, S.
    Patel, H.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S295 - S296
  • [44] The relationship between vedolizumab therapeutic drug monitoring, biomarkers of inflammation, and clinical outcomes in Inflammatory Bowel Disease in the real-world setting
    Afif, W.
    Marshall, J. K.
    Kaidanovich-Beilin, O.
    Ward, R.
    Seow, C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S063 - S064
  • [45] Safety of Vedolizumab in Inflammatory Bowel Disease Patients: Real World Experience From a Large University Practice
    Ladd, Antonio H. Mendoza
    Scott, Frank I.
    Grace, Rory
    Bownik, Hillary
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S977 - S977
  • [46] VEDOLIZUMAB DRUG LEVELS ARE NOT ASSOCIATED WITH OUTCOMES OR DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE
    Shields, Stephanie
    Seenan, John Paul
    Nowell, Emma
    Dunlop, Allan
    Galloway, Peter
    Macdonald, Jonathan
    [J]. GUT, 2021, 70 : A122 - A123
  • [47] VEDOLIZUMAB IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH IMPROVED DISEASE OUTCOMES AND LOW RATES OF SERIOUS INFECTION: A SINGLE CENTER REAL WORLD EXPERIENCE
    Pabla, Baldeep S.
    Wong, Rochelle
    Kashani, Amir
    Scoville, Elizabeth A.
    Dalal, Robin
    Beaulieu, Dawn
    Schwartz, David A.
    Horst, Sara N.
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S883 - S884
  • [48] Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Di Mario, C.
    Papa, A.
    Gremese, E.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S398 - S398
  • [49] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Haddley, K.
    [J]. DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
  • [50] Vedolizumab (Entyvio) for Inflammatory Bowel Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1451): : 86 - 88
12345